Biologics and Small Molecules in Ulcerative Colitis and Crohn's Disease: Current Evidence and Clinical Relevance
The treatment of the chronic inflammatory bowel diseases (IBD) ulcerative colitis and Crohn’s disease has made significant progress with the introduction of biologics and small molecules. In addition to conventional immunosuppressants, targeted modulators of inflammatory pathways – such as TNF-α inh...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | deu |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2025-06-01
|
| Series: | healthbook TIMES Das Schweizer Ärztejournal Journal Des Médecins Suisses |
| Online Access: | https://doi.org/10.36000/hbT.2025.17.004 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849317259717115904 |
|---|---|
| author | Stephan Vavricka |
| author_facet | Stephan Vavricka |
| author_sort | Stephan Vavricka |
| collection | DOAJ |
| description | The treatment of the chronic inflammatory bowel diseases (IBD) ulcerative colitis and Crohn’s disease has made significant progress with the introduction of biologics and small molecules. In addition to conventional immunosuppressants, targeted modulators of inflammatory pathways – such as TNF-α inhibitors, interleukin inhibitors, integrin antagonists, JAK inhibitors, and S1P receptor modulators – have become integral components of therapy. Clinical studies demonstrate that biologics like adalimumab, infliximab, and vedolizumab significantly improve remission rates, while newer IL-23 and JAK inhibitors offer promising options for therapy-refractory patients. New drug classes such as anti-TL1A antibodies and MiR124 modulators are further expanding the therapeutic spectrum.
**Zusammenfassung**
Die Behandlung der beiden chronisch-entzündlichen Darmerkrankungen (IBD) Colitis ulcerosa und Morbus Crohn hat dank der Einführung von Biologika und niedermolekularer Substanzen (small molecules) bedeutende Fortschritte gemacht. Neben klassischen Immunsuppressiva sind gezielte Modulatoren inflammatorischer Signalwege etabliert, darunter TNF-α-Inhibitoren, Interleukin-Hemmer, Integrin-Antagonisten, JAK-Inhibitoren und S1P-Rezeptormodulatoren. Klinische Studien zeigen, dass Biologika wie Adalimumab, Infliximab und Vedolizumab die Remissionsraten signifikant erhöhen, während neuere IL-23- und JAK-Inhibitoren vielversprechende Optionen für therapierefraktäre Patienten bieten. Neue Wirkstoffklassen wie Anti-TL1A-Antikörper und MiR124-Modulatoren erweitern das therapeutische Spektrum.
PEER REVIEWED ARTICLE
**Peer Reviewers:**
PD Dr. med. Jonas Zeitz
Dr. med. Samuel Truninger
Gastroenterologie und Hepatologie, HOCH Health Ostschweiz, Kantonsspital St. Gallen, St. Gallen, Schweiz
PD. Dr. med. Jonas Zeitz, Schweizer Zöliakie Zentrum, GastroZentrum Hirslanden Zürich, Zürich, Schweiz
Ein anonymer Peer Reviewer
Artikel erhalten am 28.04.2025; artikel akzeptiert nach Peer Review am 12. Juni 2025; artikel veröffentlicht am 30. Juni 2025. |
| format | Article |
| id | doaj-art-00ac1f9a6ec14f7ca7ca5fbf7f2c544d |
| institution | Kabale University |
| issn | 2673-8406 2673-8414 |
| language | deu |
| publishDate | 2025-06-01 |
| publisher | THE HEALTHBOOK COMPANY LTD. |
| record_format | Article |
| series | healthbook TIMES Das Schweizer Ärztejournal Journal Des Médecins Suisses |
| spelling | doaj-art-00ac1f9a6ec14f7ca7ca5fbf7f2c544d2025-08-20T03:51:18ZdeuTHE HEALTHBOOK COMPANY LTD.healthbook TIMES Das Schweizer Ärztejournal Journal Des Médecins Suisses2673-84062673-84142025-06-0117210.36000/hbT.2025.17.004Biologics and Small Molecules in Ulcerative Colitis and Crohn's Disease: Current Evidence and Clinical RelevanceStephan VavrickaThe treatment of the chronic inflammatory bowel diseases (IBD) ulcerative colitis and Crohn’s disease has made significant progress with the introduction of biologics and small molecules. In addition to conventional immunosuppressants, targeted modulators of inflammatory pathways – such as TNF-α inhibitors, interleukin inhibitors, integrin antagonists, JAK inhibitors, and S1P receptor modulators – have become integral components of therapy. Clinical studies demonstrate that biologics like adalimumab, infliximab, and vedolizumab significantly improve remission rates, while newer IL-23 and JAK inhibitors offer promising options for therapy-refractory patients. New drug classes such as anti-TL1A antibodies and MiR124 modulators are further expanding the therapeutic spectrum. **Zusammenfassung** Die Behandlung der beiden chronisch-entzündlichen Darmerkrankungen (IBD) Colitis ulcerosa und Morbus Crohn hat dank der Einführung von Biologika und niedermolekularer Substanzen (small molecules) bedeutende Fortschritte gemacht. Neben klassischen Immunsuppressiva sind gezielte Modulatoren inflammatorischer Signalwege etabliert, darunter TNF-α-Inhibitoren, Interleukin-Hemmer, Integrin-Antagonisten, JAK-Inhibitoren und S1P-Rezeptormodulatoren. Klinische Studien zeigen, dass Biologika wie Adalimumab, Infliximab und Vedolizumab die Remissionsraten signifikant erhöhen, während neuere IL-23- und JAK-Inhibitoren vielversprechende Optionen für therapierefraktäre Patienten bieten. Neue Wirkstoffklassen wie Anti-TL1A-Antikörper und MiR124-Modulatoren erweitern das therapeutische Spektrum. PEER REVIEWED ARTICLE **Peer Reviewers:** PD Dr. med. Jonas Zeitz Dr. med. Samuel Truninger Gastroenterologie und Hepatologie, HOCH Health Ostschweiz, Kantonsspital St. Gallen, St. Gallen, Schweiz PD. Dr. med. Jonas Zeitz, Schweizer Zöliakie Zentrum, GastroZentrum Hirslanden Zürich, Zürich, Schweiz Ein anonymer Peer Reviewer Artikel erhalten am 28.04.2025; artikel akzeptiert nach Peer Review am 12. Juni 2025; artikel veröffentlicht am 30. Juni 2025.https://doi.org/10.36000/hbT.2025.17.004 |
| spellingShingle | Stephan Vavricka Biologics and Small Molecules in Ulcerative Colitis and Crohn's Disease: Current Evidence and Clinical Relevance healthbook TIMES Das Schweizer Ärztejournal Journal Des Médecins Suisses |
| title | Biologics and Small Molecules in Ulcerative Colitis and Crohn's Disease: Current Evidence and Clinical Relevance |
| title_full | Biologics and Small Molecules in Ulcerative Colitis and Crohn's Disease: Current Evidence and Clinical Relevance |
| title_fullStr | Biologics and Small Molecules in Ulcerative Colitis and Crohn's Disease: Current Evidence and Clinical Relevance |
| title_full_unstemmed | Biologics and Small Molecules in Ulcerative Colitis and Crohn's Disease: Current Evidence and Clinical Relevance |
| title_short | Biologics and Small Molecules in Ulcerative Colitis and Crohn's Disease: Current Evidence and Clinical Relevance |
| title_sort | biologics and small molecules in ulcerative colitis and crohn s disease current evidence and clinical relevance |
| url | https://doi.org/10.36000/hbT.2025.17.004 |
| work_keys_str_mv | AT stephanvavricka biologicsandsmallmoleculesinulcerativecolitisandcrohnsdiseasecurrentevidenceandclinicalrelevance |